ES2749903T3 - Proteína quimérica - Google Patents

Proteína quimérica Download PDF

Info

Publication number
ES2749903T3
ES2749903T3 ES16717433T ES16717433T ES2749903T3 ES 2749903 T3 ES2749903 T3 ES 2749903T3 ES 16717433 T ES16717433 T ES 16717433T ES 16717433 T ES16717433 T ES 16717433T ES 2749903 T3 ES2749903 T3 ES 2749903T3
Authority
ES
Spain
Prior art keywords
cells
cell
fas
extracellular ligand
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16717433T
Other languages
English (en)
Spanish (es)
Inventor
Martin Pule
brian Philip
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Application granted granted Critical
Publication of ES2749903T3 publication Critical patent/ES2749903T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES16717433T 2015-04-13 2016-04-12 Proteína quimérica Active ES2749903T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1506223.5A GB201506223D0 (en) 2015-04-13 2015-04-13 Chimeric protein
PCT/GB2016/051019 WO2016166521A1 (en) 2015-04-13 2016-04-12 Chimeric protein

Publications (1)

Publication Number Publication Date
ES2749903T3 true ES2749903T3 (es) 2020-03-24

Family

ID=53333686

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16717433T Active ES2749903T3 (es) 2015-04-13 2016-04-12 Proteína quimérica

Country Status (10)

Country Link
US (1) US10869911B2 (https=)
EP (1) EP3283526B1 (https=)
JP (1) JP6704411B2 (https=)
CN (1) CN107531804A (https=)
AU (1) AU2016250200B2 (https=)
CA (1) CA2981846A1 (https=)
ES (1) ES2749903T3 (https=)
GB (1) GB201506223D0 (https=)
HK (1) HK1243107B (https=)
WO (1) WO2016166521A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201519900D0 (en) * 2015-11-11 2015-12-23 Ucl Business Plc Chimeric antigen receptor
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
GB201716728D0 (en) 2017-10-12 2017-11-29 Autolus Ltd Cell
AU2019403393B2 (en) * 2018-12-20 2026-04-16 The University Of Chicago Methods and compositions related to therapeutic peptides for cancer therapy
WO2021102250A1 (en) * 2019-11-21 2021-05-27 Luppino Francesco Growth factor restoration
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
WO2021198163A1 (en) * 2020-04-01 2021-10-07 Medigene Immunotherapies Gmbh Cd3-fusion protein and uses thereof
EP4199947A4 (en) 2020-08-18 2024-10-16 Onchilles Pharma, Inc. Modified porcine pancreatic elastase proteins
JP2024527882A (ja) * 2021-07-21 2024-07-26 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジー 新規のキメラ抗原受容体及びそれを発現する免疫細胞
AU2023400596A1 (en) * 2022-11-29 2025-06-19 Malcorp Biodiscoveries Limited Novel cd20 protein
CA3278900A1 (en) 2023-03-31 2024-10-03 AbelZeta Inc. BISPECIFIC CHIMERIC ANTIGENIC RECEPTORS TARGETING CD20 AND BCMA

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914650D0 (en) * 1999-06-24 1999-08-25 Angyogene Pharmaceuticals Ltd Chimeric proteins mediating targeted apoptosis
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
DK2496698T3 (en) * 2009-11-03 2019-04-15 Hope City TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION
ES2649991T3 (es) 2012-11-19 2018-01-16 Baliopharm Ag Anticuerpo biespecífico recombinante que se une a CD20 y CD95
JP2017100947A (ja) * 2014-03-31 2017-06-08 株式会社オーダーメードメディカルリサーチ 目的抗原に対する抗体の作製方法

Also Published As

Publication number Publication date
CN107531804A (zh) 2018-01-02
GB201506223D0 (en) 2015-05-27
HK1243107B (en) 2020-05-08
JP6704411B2 (ja) 2020-06-03
JP2018512154A (ja) 2018-05-17
EP3283526A1 (en) 2018-02-21
CA2981846A1 (en) 2016-10-20
US10869911B2 (en) 2020-12-22
US20180169189A1 (en) 2018-06-21
WO2016166521A1 (en) 2016-10-20
AU2016250200A1 (en) 2017-10-26
EP3283526B1 (en) 2019-09-04
AU2016250200B2 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
ES2749903T3 (es) Proteína quimérica
US11103532B2 (en) Chimeric protein
JP7082046B2 (ja) 受容体
CA3111384A1 (en) Allogeneic cell compositions and methods of use
JP2017537622A (ja) がんを治療するための方法及び組成物
HK1243107A1 (en) Chimeric protein
CN109476722A (zh) 用于改善免疫细胞的功效和扩张的方法
ES2927220T3 (es) Composiciones y procedimientos de módulos suicidas
CN107847585A (zh) 用于得到体内存留性和治疗活性的nkt细胞亚群以及其繁殖
KR20220007675A (ko) 아세틸콜린 수용체 키메라 자가항체 수용체 세포의 조성물 및 방법
JP2023520572A (ja) オルソゴナルな受容体を発現するようにゲノムが改変されたヒト免疫細胞
TWI843716B (zh) hTERT特異性結合分子
CN113195528A (zh) 对ha-1h特异的结合蛋白及其用途
US20250108069A1 (en) Chimeric adaptor polypeptides
WO2024042318A1 (en) Chimeric antigen receptor (car) to a tcr beta-chain variable region
HK40105414A (zh) 突变体il-15组合物及其方法
HK40050291B (en) Suicide module compositions and methods
HK1236005A1 (en) Chimeric protein
HK1236005B (en) Chimeric protein